Evidence map›Paper›PMID 41831103›Full record

ArticleDiscover oncology2026

A machine learning framework predicts oncogenic driver mutations from SNP profiles in lung adenocarcinoma.

Junyu Li, Zuxiu Wang, Yuchen Xia, Qiaxuan Li, Shuo Yin, Weimin Mao, Peimeng You

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junyu Li *Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Zuxiu Wang *The School of Basic Medical Sciences of Xuzhou Medical University, Xuzhou, 221000, China.
Yuchen XiaDepartment of Radiation Oncology, Cancer Hospital of Nanchang University, Nanchang, 330029, Jiangxi, China.
Qiaxuan LiDepartment of Lung Transplantation, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Shuo YinCollege of Basic Medical Sciences, Capital Medical University, beijing, China, 100069. aaronyin@mail.ccmu.edu.cn.
Weimin Mao *Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. maowm@zjcc.org.cn.
Peimeng YouDepartment of Biomedical engineering, Capital Medical University, Beijing, 100071, China. ncuypm0003@163.com.

Funding

Innovation Program of Jiangxi Health Committee (No.2023ZD005)Natural Science Foundation of Jiangxi (20192BAB205065)Natural Science Foundation of Jiangxi (20252BAC240437)Wu Jieping Medical Foundation-Special Research Grant Program (320.6750.2023-5-33)
6 · The paper itself

Abstract

backgroundThis study aims to explore a new application paradigm of single nucleotide polymorphisms (SNP) in precision treatment of lung adenocarcinoma by integrating genomics and machine learning techniques.

methodsThis study is based on a cohort of 83 lung adenocarcinoma patients diagnosed by pathology. Clinical features and SNP genotype data are integrated, and a gradient boosting decision tree (GBDT) algorithm is used to establish an SNPdriver prediction framework. By adaptively learning the nonlinear interaction effects between SNP features, binary classification prediction of driving factors is achieved.

resultsThis study randomly divided 83 patients with lung adenocarcinoma into 7:3 groups, and there was no significant difference in baseline characteristics (p > 0.05). The SNPdriver model based on GBDT adopts a 6-decision tree ensemble architecture and achieves mutation state weighted prediction through feature path splitting. The validation showed that the predicted Area Under the Curve (AUC) for EGFR and KRAS mutations were 0.90 and 0.85, respectively, and the calibration curve confirmed that the predicted probability was highly consistent with the actual incidence rate.

conclusionsThis study successfully constructed the SNPdriver model for predicting driver gene mutations in lung adenocarcinoma based on SNP feature networks. Its high discriminatory power and clinical consistency validated the potential of SNPs as multi-gene coregulatory biomarkers.

Indexed as

Driver gene mutationGradient boosting decision treeMachine learningNon-small cell lung cancer

Identifiers

PMID41831103
PMCPMC13100186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.